Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun;22(2):161-8.
doi: 10.4104/pcrj.2013.00017.

Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study

David Price  1 , Amanda J Lee, Erika J Sims, Linda Kemp, Elizabeth V Hillyer, Alison Chisholm, Julie von Ziegenweidt, Angela Williams
Affiliations

Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study

David Price et al. Prim Care Respir J. 2013 Jun.

Abstract

Background: Patient preference is an important factor when choosing an inhaler device for asthma or chronic obstructive pulmonary disease (COPD).

Aims: To identify characteristics of patients with asthma or COPD who prefer a once-daily controller medication regimen.

Methods: This retrospective observational study used electronic patient records and linked outcomes from patient-completed questionnaires in a primary care database. We compared the characteristics of patients indicating a preference for once-daily therapy with those who were unsure or indicating no preference.

Results: Of 3,731 patients with asthma, 2,174 (58%) were women; the mean age was 46 years (range 2-94). Of 2,138 patients with COPD, 980 (46%) were women; the mean age was 70 years (range 35-98). Approximately half of the patients in each cohort indicated once-daily preference, one-quarter were unsure, and one-quarter did not prefer once-daily therapy. In patients with asthma or COPD, the preference for once-daily controller medication was significantly associated with poor adherence and higher concerns about medication. In asthma, good control and low self-perceived controller medication need were associated with once-daily preference. By contrast, in COPD, a high self-perceived need for controller medication was associated with once-daily preference. There was no significant relationship between once-daily preference and age, sex, disease severity, or exacerbation history.

Conclusions: Understanding patient preferences may help prescribers to individualise therapy better for asthma and COPD.

PubMed Disclaimer

Conflict of interest statement

DP has consultant arrangements with Almirral, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Medapharma, Novartis, Napp, Nycomed, Pfizer, Sandoz, and Teva. He or his research team have received grants and support for research in respiratory disease from the following organisations in the last 5 years: UK National Health Service, Aerocrine, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Novartis, Nycomed, Orion, Pfizer, and Teva. He has spoken for Almirral, AstraZeneca, Activaero, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Novartis, Merck, Mundipharma, Pfizer, and Teva. He has shares in AKL Ltd which produces phytopharmaceuticals. He is the sole owner of Research in Real Life Ltd and its subsidiary social enterprise Optimum Patient Care. AJL receives ad hoc payment for statistical consultancy with RIRL. EJS and JvZ are employees of RiRL. EVH is a consultant to RiRL and has done freelance writing work for Merck, Aerocrine, and TevaFrance. At the time this study was conducted, LK and AC were employees of RiRL and AW was an employee of GSK R&D.

Figures

Figure 1
Figure 1. Patients' level of agreement with a statement indicating preference for once-daily therapy
See this image and copyright information in PMC

Comment in

References

    1. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization, 2003.
    1. Cutler DM, Everett W. Thinking outside the pillbox—medication adherence as a priority for health care reform. N Engl J Med 2010;362(17):1553–5. http://dx.doi.org/10.1056/NEJMp1002305 - PubMed
    1. Hasford J, Uricher J, Tauscher M, Bramlage P, Virchow JC. Persistence with asthma treatment is low in Germany especially for controller medication: a population based study of 483,051 patients. Allergy 2010;65(3):347–54. http://dx.doi.org/10.1111/j.1398-9995.2009.02161.x - PubMed
    1. Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest 2000;117(2):542–50. http://dx.doi.org/10.1378/chest.117.2.542 - PubMed
    1. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008;63(9):831–8. http://dx.doi.org/10.1136/thx.2007.086041 - PMC - PubMed

Publication types

MeSH terms

Substances